Inozyme Pharma Announces FDA Fast Track Designation For INZ-701, For The Treatment Of ABCC6 Deficiency
Author: Benzinga Newsdesk | July 02, 2024 08:33am
Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to INZ-701 for the treatment of ABCC6 Deficiency.
Posted In: INZY